Comparison of discontinuation rates and mean ruxolitinib dosing over time in study INCB18424-251. (A) Kaplan-Meier estimates of discontinuation rates in patients enrolled from MDACC and Mayo Clinic Rochester. At 6 months, discontinuations at the Mayo Clinic Rochester were much higher than those observed at the MDACC Center. (B) Mean total daily dose of ruxolitinib at the MDACC was much higher than that for patients enrolled at the Mayo Clinic Rochester and was similar to the mean total daily dose of ruxolitinib in COMFORT-I (31 mg).